-
1
-
-
79952486262
-
Amyotrophic lateral sclerosis
-
Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-55.
-
(2011)
Lancet
, vol.377
, pp. 942-955
-
-
Kiernan, M.C.1
Vucic, S.2
Cheah, B.C.3
-
2
-
-
84857537860
-
A proposed staging system for amyotrophic lateral sclerosis
-
Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135(Pt 3):847-52.
-
(2012)
Brain
, vol.135
, pp. 847-852
-
-
Roche, J.C.1
Rojas-Garcia, R.2
Scott, K.M.3
-
3
-
-
84901494031
-
Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis
-
Jones A, Jivraj N, Balendra R, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014. doi:10.3109/21678421.2013.872149
-
(2014)
Amyotroph Lateral Scler Frontotemporal Degener
-
-
Jones, A.1
Jivraj, N.2
Balendra, R.3
-
4
-
-
77949314446
-
Motor neuron disease: The bare essentials
-
Talbot K. Motor neuron disease: the bare essentials. Pract Neurol 2009;9:303-9.
-
(2009)
Pract Neurol
, vol.9
, pp. 303-309
-
-
Talbot, K.1
-
5
-
-
0038480212
-
Prolonged survival in motor neuron disease: A descriptive study of the King's database 1990-2002
-
Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 2003;74:995-7.
-
(2003)
J Neurol Neurosurg Psychiatry
, vol.74
, pp. 995-997
-
-
Turner, M.R.1
Parton, M.J.2
Shaw, C.E.3
-
6
-
-
85015507759
-
A Phase 2 - 3 trial of olesoxime in subjects with amyotrophic lateral sclerosis, 23rd International Symposium on ALS/MND Abstracts
-
A Phase 2 - 3 trial of olesoxime in subjects with amyotrophic lateral sclerosis, 23rd International Symposium on ALS/MND Abstracts. Amyotroph Lateral Scler 2012;13 (S1):1-58.
-
(2012)
Amyotroph Lateral Scler
, vol.13
, Issue.S1
, pp. 1-58
-
-
-
7
-
-
80053175592
-
Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS)
-
Eudract number: 2008-006891-31
-
Al-Chalabi A, Shaw PJ, Young CA, et al. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]. BMC Neurol 2011;11:111.
-
(2011)
BMC Neurol
, vol.11
, pp. 111
-
-
Al-Chalabi, A.1
Shaw, P.J.2
Young, C.A.3
-
8
-
-
84875273042
-
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial
-
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013;12:339-45.
-
(2013)
Lancet Neurol
, vol.12
, pp. 339-345
-
-
-
9
-
-
0034574407
-
El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
-
Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000;1:293-9.
-
(2000)
Amyotroph Lateral Scler
, vol.1
, pp. 293-299
-
-
Brooks, B.R.1
Miller, R.G.2
Swash, M.3
-
10
-
-
0032692481
-
The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)
-
Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
-
(1999)
J Neurol Sci
, vol.169
, pp. 13-21
-
-
Cedarbaum, J.M.1
Stambler, N.2
Malta, E.3
-
11
-
-
84873902183
-
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
-
Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Invest 2011;1:1375-89.
-
(2011)
Clin Invest
, vol.1
, pp. 1375-1389
-
-
Berry, J.D.1
Cudkowicz, M.E.2
-
13
-
-
70450158934
-
The natural history of ALS is changing: Improved survival
-
Qureshi M, Schoenfeld DA, Paliwal Y, et al. The natural history of ALS is changing: Improved survival. Amyotroph Lateral Scler 2009;10(5-6): 324-31.
-
(2009)
Amyotroph Lateral Scler
, vol.10
, Issue.5-6
, pp. 324-331
-
-
Qureshi, M.1
Schoenfeld, D.A.2
Paliwal, Y.3
-
14
-
-
33744809339
-
Clinical trials in ALS: What did we learn from recent trials in humans?
-
Meininger V. Clinical trials in ALS: what did we learn from recent trials in humans? Neurodegener Dis 2005;2(3-4):208-14.
-
(2005)
Neurodegener Dis
, vol.2
, Issue.3-4
, pp. 208-214
-
-
Meininger, V.1
-
15
-
-
47249154380
-
Therapy development for ALS: Lessons learned and path forward
-
Lanka V, Cudkowicz M. Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler 2008;9:131-40.
-
(2008)
Amyotroph Lateral Scler
, vol.9
, pp. 131-140
-
-
Lanka, V.1
Cudkowicz, M.2
-
16
-
-
0035015186
-
Clinical trials: Present and future
-
Mitsumoto H. Clinical trials: present and future. Amyotroph Lateral Scler 2001;2:S10-4.
-
(2001)
Amyotroph Lateral Scler
, vol.2
, pp. S10-S14
-
-
Mitsumoto, H.1
-
17
-
-
80755128213
-
Clinical diagnosis and management of amyotrophic lateral sclerosis
-
Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639-49.
-
(2011)
Nat Rev Neurol
, vol.7
, pp. 639-649
-
-
Hardiman, O.1
Van Den Berg, L.H.2
Kiernan, M.C.3
-
18
-
-
84919719348
-
Development of a clinical staging system for amyotrophic lateral sclerosis
-
(Meeting Abstracts 1):P07.071
-
Chio A, Hammond E, Mora G, et al. Development of a clinical staging system for amyotrophic lateral sclerosis. Neurology 2013;80(Meeting Abstracts 1):P07.071.
-
(2013)
Neurology
, vol.80
-
-
Chio, A.1
Hammond, E.2
Mora, G.3
-
19
-
-
0033905620
-
Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study
-
Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000;57:1171-6.
-
(2000)
Arch Neurol
, vol.57
, pp. 1171-1176
-
-
Traynor, B.J.1
Codd, M.B.2
Corr, B.3
-
20
-
-
79952199408
-
Progression in ALS is not linear but is curvilinear
-
Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. J Neurol 2010;257:1713-17.
-
(2010)
J Neurol
, vol.257
, pp. 1713-1717
-
-
Gordon, P.H.1
Cheng, B.2
Salachas, F.3
-
21
-
-
0033595524
-
Nutritional status is a prognostic factor for survival in ALS patients
-
Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999;53:1059-63.
-
(1999)
Neurology
, vol.53
, pp. 1059-1063
-
-
Desport, J.C.1
Preux, P.M.2
Truong, T.C.3
-
22
-
-
79955756864
-
Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients
-
Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosur Psychiatry 2011;82:628-34.
-
(2011)
J Neurol Neurosur Psychiatry
, vol.82
, pp. 628-634
-
-
Marin, B.1
Desport, J.C.2
Kajeu, P.3
-
23
-
-
33744816556
-
Hypermetabolism in ALS: Correlations with clinical and paraclinical parameters
-
Desport JC, Torny F, Lacoste M, et al. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2005;2:202-7.
-
(2005)
Neurodegener Dis
, vol.2
, pp. 202-207
-
-
Desport, J.C.1
Torny, F.2
Lacoste, M.3
-
24
-
-
4544262980
-
Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis
-
Higo R, Tayama N, Nito T. Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis. Auris Nasus Larynx 2004;31:247-54.
-
(2004)
Auris Nasus Larynx
, vol.31
, pp. 247-254
-
-
Higo, R.1
Tayama, N.2
Nito, T.3
-
26
-
-
0024825916
-
Bulbar amyotrophic lateral sclerosis: Patterns of progression and clinical management
-
Hillel AD, Miller R. Bulbar amyotrophic lateral sclerosis: patterns of progression and clinical management. Head Neck 1989;11:51-9.
-
(1989)
Head Neck
, vol.11
, pp. 51-59
-
-
Hillel, A.D.1
Miller, R.2
-
27
-
-
70350149848
-
Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology
-
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218-26.
-
(2009)
Neurology
, vol.73
, pp. 1218-1226
-
-
Miller, R.G.1
Jackson, C.E.2
Kasarskis, E.J.3
-
28
-
-
84866093307
-
What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis?
-
Pena MJ, Ravasco P, Machado M, et al. What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis? Amyotroph Lateral Scler 2012;13:550-4.
-
(2012)
Amyotroph Lateral Scler
, vol.13
, pp. 550-554
-
-
Pena, M.J.1
Ravasco, P.2
Machado, M.3
-
29
-
-
79952257244
-
Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease
-
Katzberg HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2011;(1):CD004030.
-
(2011)
Cochrane Database Syst Rev
, Issue.1
-
-
Katzberg, H.D.1
Benatar, M.2
-
30
-
-
0141614836
-
Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction
-
Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler 2003;4:177-85.
-
(2003)
Amyotroph Lateral Scler
, vol.4
, pp. 177-185
-
-
Mitsumoto, H.1
Davidson, M.2
Moore, D.3
|